Cambridge, MA-based Moderna, Inc. MRNA is a clinical-stage pharmaceutical company primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company does not have any marketed products in its portfolio. It derives revenues from its collaboration pa
Investors are always looking for stocks that are poised to beat at earnings season and Baidu, Inc. BIDU may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Baidu is seeing favorable earning
Investors are always looking for stocks that are poised to beat at earnings season and Sage Therapeutics, Inc. SAGE may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
Ionis Pharmaceuticals (IONS) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $2.42 per share a year ago. These figures are adjusted for non-recurring items.
AMC Networks (AMCX) came out with quarterly earnings of $1.69 per share, missing the Zacks Consensus Estimate of $1.73 per share. This compares to earnings of $1.92 per share a year ago. These figures are adjusted for non-recurring items.
Wendy's (WEN) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items.
FTI Consulting, Inc. FCN delivered mixed fourth-quarter 2019 results, with earnings missing the Zacks Consensus Estimate but revenues beating the same.
On Feb 25, we issued an updated research report on Carpenter Technology Corporation CRS. The company’s efforts to strengthen customer relationships, execution of its commercial strategy, acquisitions and investments in additive manufacturing will fuel growth. Also, solid deman
Unless you've been hiding under a rock, you've been hearing a lot about the coronavirus, which is dominating investors' minds this week and driving down equity indices around the world.
Dycom Industries (DY) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for non-recurring items.
Drinks giant Diageo warned the coronavirus outbreak could hit profits by up to £200 million in 2020, as companies began to measure the impact of the epidemic.
London's blue-chip stocks are set to gain modestly this year although the outlook is coloured by the British government's determination to stick to the end-December deadline for a trade deal with the European Union, a Reuters poll found.
Russia's stock market is forecast to surpass record levels reached in January by the end of this year, a Reuters poll of market experts showed, but concerns over the effects of China's coronavirus epidemic are causing uncertainty.
Analysts are scaling back their bullish forecasts for gains in Japanese shares, as the spreading coronavirus outbreak has raised recession risks and cast a pall over the outlook for corporate earnings, a Reuters poll showed.
South Korea likely snapped 14 months of declining exports in February, due to more working days in the month although analysts expect Asia's fourth-largest economy to show a sharp hit to trade from the coronavirus outside the headline figure.
Systemax (SYX) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for non-recurring items.
Darling Ingredients (DAR) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.24 per share a year ago. These figures are adjusted for non-recurring items.
Checked
22 minutes 3 seconds ago
This feed is responsible for generating the rss feed related to the topic Stocks